4D Molecular Therapeutics FDMT
4D Molecular Therapeutics Q3 FY23: revenue $20.2M; diluted EPS −$0.24
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-23-062103
- Document
- 10-Q
- Exhibit 10.1
- Material contract
Key figures from this report
These are the numbers 4D Molecular Therapeutics reported for Q3 FY23, the quarter ended Sep 30, 2023, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$20.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$10.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.24No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$275.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$1.2MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- XOMA Royalty XOMA public float $168M, Jun 30, 2025
- Lexicon Pharmaceuticals LXRX public float $170M, Jun 30, 2025
- Lineage Cell Therapeutics LCTX public float $162M, Jun 30, 2025
- Omeros OMER public float $172M, Jun 30, 2025
- Forte Biosciences FBRX public float $157M, Jun 30, 2025